Dec 5, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announced a poster presentation at the 66th ASH Annual Meeting and Exposition, taking place December 7-10, 2024, in San Diego, California, and online. Meanwhile, the First Affiliated Hospital of Guangxi Medical University, the collaborator of the CS-101 clinical trial, will give an oral presentation about the clinical result of β-thalessemia at the meeting.
Presentation Title: Rapid, Efficient and Durable Fetal Hemoglobin Production Following CS-101 Treatment in Transfusion-Dependent β-Thalassemia Participants: An Autologous, Ex Vivo Edited CD34+ Stem Cell Product Using the Innovative Transformer Base Editor (tBE)
Session Name: 801. Gene Therapies: Poster III
Time: Monday, December 9, 2024, 6:00 PM-8:00 PM (PST)
Location: San Diego Convention Center, Halls G-H
Format: Poster presentation
Presentation Title: A Multi-Center Clinical Trial of Allogeneic Hematopoietic Stem Cell Transplants in Transfusion Dependent Thalassemia
Speaker: Prof. Rongrong Liu, The First Affiliated Hospital of Guangxi Medical University
Time: Saturday, December 7, 2024, 5:15 PM (PST)
Location: San Diego Convention Center, Room 6DE
Format: Oral presentation
For more information about the meeting, visit: https://www.hematology.org/meetings/annual-meeting
About CorrectSequence Therapeutics
CorrectSequence TherapeuticsTM (CorrectseqTM) (www.xmyhtsm.com) is a clinical stage biotechnology company employing its proprietary transformer Base Editor (tBE) to pioneer next-generation gene editing therapies.
Our leading pipeline candidate, CS-101, utilizing innovative base editor targeting HBG, curing β-hemoglobinopathies, has obtained IND approval from the China NMPA. More than 10 transfusion-dependent β-thalassemia patients have been treated with CS-101 and achieved transfusion independence. The clinical performance on sickle cell disease with CS-101 is also under investigation. Clinical data demonstrate its superior performance, indicating significant potential for CS-101 to become a best-in-class gene editing therapy for curing patients with β-hemoglobinopathies.
Multiple pipelines for genetic diseases, metabolic disorders, cardiovascular diseases are well underway. We focus on biotechnology innovation, research and development and are committed to providing efficient, reliable and safe solution for unmet medical needs.
